Document Detail

Prospective open label study of solifenacin for overactive bladder in children.
MedLine Citation:
PMID:  20728124     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We evaluated the effect of solifenacin for urinary incontinence in children with overactive/neurogenic bladder refractory to oxybutynin or tolterodine. MATERIALS AND METHODS: Pediatric patients presenting with refractory overactive bladder with incontinence were offered the opportunity to enter a prospective, open label protocol using adjusted dose regimens of 1.25 to 10 mg solifenacin. Study inclusion criteria were absent correctable neurological anomalies on magnetic resonance imaging, failure of symptoms to improve on intensive behavioral and medical (oxybutynin or tolterodine) therapy, and/or significant side effects of those agents. Followup consisted of a voiding diary, post-void residual urine measurement, urine culture, ultrasound and urodynamics. Families were questioned about continence, side effects, compliance, behavior change and quality of life. The primary end point was efficacy for continence and secondary end points were tolerability and safety. RESULTS: Enrolled in the study were 42 girls and 30 boys. Of the patients 27 with neurogenic bladder, of whom 11 were on clean intermittent catheterization, and 45 with overactive bladder completed a minimum 3-month followup. Patients were on solifenacin a mean of 15.6 months. Mean age at study initiation was 9.0 years. Mean ± SD urodynamic capacity improved from 146 ± 64 to 311 ± 123 ml and uninhibited contractions decreased from 70 ± 29 to 20 ± 19 cm H(2)O (p <0.01). Continence improved in all patients, including 24 who were dry, and 42 and 6 who were significantly and moderately improved, respectively. Of the patients 50 reported no side effects while 15 had mild and 3 had moderate side effects. Four patients withdrew from the protocol due to intolerable side effects. Four patients had significant post-void residual urine (greater than 20 ml). CONCLUSIONS: In children with overactive bladder refractory to oxybutynin or tolterodine solifenacin is an effective alternative to improve symptoms. Tolerability was acceptable and the adjusted dose regimen appeared safe.
Stéphane Bolduc; Katherine Moore; Geneviève Nadeau; Sylvie Lebel; Pascale Lamontagne; Micheline Hamel
Related Documents :
7484524 - Quality of life assessment in heterotopic and orthotopic neobladder reconstruction: a c...
17869054 - The s-shaped orthotopic ileal neobladder substitute incorporating a new seromuscular an...
16184994 - Acetabular coverage in bladder exstrophy: role of 3-dimensional computed tomography.
7776454 - Further experience with the modified ileal ureter.
24628894 - Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotre...
19196254 - The level of urinary secretory immunoglobulin a (siga) of patients with iga nephropathy...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2010-08-21
Journal Detail:
Title:  The Journal of urology     Volume:  184     ISSN:  1527-3792     ISO Abbreviation:  J. Urol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-13     Completed Date:  2010-11-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1668-73     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Division of Urology, Centre Hospitalier Universitaire de Québec, Université Laval, Québec, Québec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Muscarinic Antagonists / therapeutic use*
Prospective Studies
Quinuclidines / therapeutic use*
Tetrahydroisoquinolines / therapeutic use*
Urinary Bladder, Neurogenic / drug therapy*
Urinary Bladder, Overactive / drug therapy*
Urinary Incontinence / drug therapy*
Reg. No./Substance:
0/Muscarinic Antagonists; 0/Quinuclidines; 0/Tetrahydroisoquinolines; 0/quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Progression of Renal Insufficiency in Children and Adolescents With Neuropathic Bladder is Not Accel...
Next Document:  Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia.